Have you noticed someone get an injury, but even long after that, blood keeps flowing out. That’s the body’s inability to make blood clots, which is needed to stop bleeding. This is the disorder – Haemophilia. This is mostly inherited genetic disorder but can be treated if diagnosed early. It is estimated that 10%-80% of people with haemophilia are present in developing countries like India as mentioned in NCBI. However, these cases remain under-diagnosed whereas most of them are not registered.
Over the years awareness about haemophilia has increased and has helped people in early diagnosis. Along with this the improvement in the health sector at public and private sectors have helped in addressing this issue to a huge extent. Centers have aimed to gather professionals as hemophilia care improves, who can provide comprehensive care and develop laboratory facilities for the detection and periodic screening of inhibitors. Coagulation laboratories have come up in a standardized fashion at most places.
Treatment and treatment products
The missing clotting factors injected into the bloodstream through needle. Bleeding stops when the clotting factor reaches the injured spot. Bleeding should be treated as soon as possible. With adequate treatment products and proper care, haemophilia patients can live perfectly healthy and normal lives.
Factor concentrates can be made from human blood (plasma-derived products) or manufactured using genetically engineered cells that carry a human factor gene (called recombinant products). Factor concentrates are made in sophisticated manufacturing facilities. All commercially prepared factor concentrates are treated to remove or inactivate blood-borne viruses.
Cryoprecipitate is derived from blood and contains a moderately high concentration of clotting factor VIII (but not IX). It is effective for joint and muscle bleeds, but is less safe from viral contamination than concentrates and is harder to store and administer. Cryoprecipitate can be made at local blood collection facilities.
In fresh frozen plasma (FFP) the red cells have been removed, leaving the blood proteins including clotting factors VIII and IX. It is less effective than cryoprecipitate for the treatment of hemophilia A because the factor VIII is less concentrated. Large volumes of plasma must be transfused, which can lead to a complication called circulatory overload. FFP is still the only product available for treatment of hemophilia A and B in some countries.
Everyday so much of blood is required for immediate treatment of haemophilia. So come forward and help donate blood through MillionGenie to let someone lead a healthy life.